SODIUM ACETATE INJECTION USP 328 MG
SODIUM ACETATE 328 MG · DIN 02181746 · OMEGA LABORATORIES LIMITED
Health Canada status: MARKETED

What is SODIUM ACETATE INJECTION USP?
SODIUM ACETATE INJECTION USP 328 MG contains SODIUM ACETATE 328 MG. It is listed in the Health Canada Drug Product Database under DIN 02181746, held by OMEGA LABORATORIES LIMITED, supplied as Solution for Intravenous administration. Health Canada currently lists it as marketed, status dated 11-Jan-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SODIUM ACETATE INJECTION USP used for?
Sodium Acetate Injection USP is indicated as a source of sodium, for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02181746 |
|---|---|
| Brand name | SODIUM ACETATE INJECTION USP |
| Generic / active ingredient | SODIUM ACETATE 328 MG |
| Manufacturer | OMEGA LABORATORIES LIMITED |
| Strength | 328 MG |
| Dosage form | Solution |
| Route of administration | Intravenous |
| Schedule | ETHICAL |
| ATC code | B05XA08 SODIUM ACETATE |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jan-2024 |
| Original market date | 1999-05-28 00:00:00 |
How is it administered?
Sodium Acetate Injection USP is administered intravenously only after dilution in a larger volume of intravenous fluids. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of milliequivalents (mEq) of sodium with an equal number of acetate. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Protect from light. Store between 15 °C and 30 °C. Do not freeze. Discard unused portion.
How is it supplied?
Single use vials of 50 mL in boxes of 10.
Contraindications
Sodium Acetate Injection USP is contraindicated in patients with hypernatremia or fluid retention.
Warnings and precautions
Sodium Acetate Injection USP must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overloading resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium-free solutions may result in significant hypokalemia.
Is SODIUM ACETATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B05XA08 SODIUM ACETATE. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SODIUM ACETATE INJECTION, USP | 328 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02139529 |
| 16.4% SODIUM ACETATE INJECTION, USP | 16.4 % | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02247204 |
| SODIUM ACETATE INJ 328MG/ML USP | 328 MG | LIQUID | SABEX INC | CANCELLED POST MARKET | DIN 00780642 |
| SODIUM ACETATE INJ 328MG/ML USP | 328 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 01944843 |
Who else supplies SODIUM ACETATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SODIUM ACETATE appears in 5432 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.